Shots:

• SomaLogic collaborate with the FDA to identify circulating pharmacodynamic biomarkers and analytical approaches that could be used to demonstrate bio-similarity of biosimilar to a reference FDA-approved biologic drug
• The collaboration will utilize the SomaLogic proteomic technology for the identification of circulating pharmacodynamic biomarkers for therapeutic biologics
• SomaLogic’s SomaScan platform makes 5-000 protein measurements simultaneously in small samples of blood- to compare changes in circulating proteins following treatment with FDA-approved biologics and could reduce the need for costly and lengthy comparative clinical studies

  Ref: GlobeNewswire | Image: SomaLogic